Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer

Mark A. Dykstra, Noah Switzer, Roman Eisner, Victor Tso, Rae Foshaug, Kathleen Ismond, Richard Fedorak, Haili Wang

Open source

DOI
10.3892/mco.2017.1407
Published
2017-09-01
Container
Molecular and Clinical Oncology
Publisher
Spandidos Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3892/mco.2017.1407,
  title = {Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer},
  author = {Mark A. Dykstra and Noah Switzer and Roman Eisner and Victor Tso and Rae Foshaug and Kathleen Ismond and Richard Fedorak and Haili Wang},
  year = {2017},
  journal = {Molecular and Clinical Oncology},
  doi = {10.3892/mco.2017.1407},
  url = {https://doi.org/10.3892/mco.2017.1407}
}

RIS

TY  - JOUR
TI  - Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
AU  - Mark A. Dykstra
AU  - Noah Switzer
AU  - Roman Eisner
AU  - Victor Tso
AU  - Rae Foshaug
AU  - Kathleen Ismond
AU  - Richard Fedorak
AU  - Haili Wang
PY  - 2017
JO  - Molecular and Clinical Oncology
DO  - 10.3892/mco.2017.1407
UR  - https://doi.org/10.3892/mco.2017.1407
ER  - 

APA

Dykstra, M. A., Switzer, N., Eisner, R., Tso, V., Foshaug, R., Ismond, K., Fedorak, R., & Wang, H. (2017). Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2017.1407

Source records